GS24-B047 / GeneScience - LARVOL DELTA

GS24-B047, a potential best-in-class DLL3-targeting T-cell engager with integrated costimulatory signal, for the treatment of small cell lung cancer (AACR 2026) - "While T-cell engagers (TCEs) targeting DLL3 and CD3, such as Tarlatamab, have demonstrated clinical activity, maintaining T-cell function in the tumor microenvironment remains challenging, and improvements in progression-free survival (PFS) have been limited. GS24-B047 is a novel DLL3-targeting TCE with integrated costimulation that promotes potent and sustained anti-tumor immunity in preclinical SCLC models. Collectively, our data support GS24-B047 as a potential therapeutic candidate for SCLC and warrant further evaluation in IND-enabling studies."

Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3 • IL6